This Article Full Text Full Text (PDF) All Versions of this Article: 20/7/1688    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, M. Articles by Miller, L. J. Search for Related Content PubMed PubMed Citation Articles by Dong, M. Articles by Miller, L. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Differential Spatial Approximation between Secretin and Its Receptor Residues in Active and Inactive Conformations Demonstrated by Photoaffinity Labeling

Cancer Center and Department of Molecular Pharmacology and Experimental Therapeutics (M.D., K.H., D.I.P., L.J.M.), Mayo Clinic, Scottsdale, Arizona 85259; and Commonwealth Biotechnologies, Inc. (N.M.), Richmond, Virginia 23235

Address all correspondence and requests for reprints to: Laurence J. Miller, M.D., Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, Arizona 85259. E-mail: miller{at}mayo.edu.

Understanding of the conformational changes in G protein-coupled receptors associated with activation and inactivation is of great interest. We previously used photoaffinity labeling to elucidate spatial approximations between photolabile residues situated throughout the pharmacophore of secretin agonist probes and this receptor. The aim of the current work was to develop analogous photolabile secretin antagonist probes and to explore their spatial approximations. The most potent secretin antagonist reported is a pseudopeptide ([^{4, 5}]secretin) in which the peptide bond between residues 4 and 5 was replaced by a (CH₂-NH) peptide bond isostere. We have developed a series of [^{4, 5}]secretin analogs incorporating photolabile benzoyl phenylalanine residues in positions 6, 22, and 26. Each bound to the secretin receptor saturably and specifically, with affinity similar to their parental peptide. At concentrations with no measurable agonist activity, each probe covalently labeled the secretin receptor. Peptide mapping using proteolytic cleavage, immunoprecipitation, and radiochemical sequencing identified that each of these three probes labeled the amino terminus of the secretin receptor. Whereas the position 22 probe labeled the same residue as its analogous agonist probe and the position 6 probe labeled a residue within two residues of that labeled by its analogous agonist probe, the position 26 probe labeled a site 16 residues away from that labeled by its analogous agonist probe. Thus, whereas structurally related agonist and antagonist probes dock in the same general region of this receptor, conformational differences in active and inactive states result in substantial differences in spatial approximation at the carboxyl-terminal end of secretin analogs.

This article has been cited by other articles:

				C. S. Lisenbee, K. G. Harikumar, and L. J. Miller Mapping the Architecture of Secretin Receptors with Intramolecular Fluorescence Resonance Energy Transfer Using Acousto-Optic Tunable Filter-Based Spectral Imaging Mol. Endocrinol., August 1, 2007; 21(8): 1997 - 2008. [Abstract] [Full Text] [PDF]